Want to see VOR full AI Analyst Report?

Vor Biopharma (VOR) Price & Analysis

Q: What was Vor Biopharma, Inc.’s price range in the past 12 months?

Vor Biopharma, Inc. lowest stock price was $6.50 and its highest was $50.20 in the past 12 months.

Q: What is Vor Biopharma, Inc.’s market cap?

Vor Biopharma, Inc.’s market cap is $1.38B.

Q: When is Vor Biopharma, Inc.’s upcoming earnings report date?

Vor Biopharma, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 88 days.

Q: How were Vor Biopharma, Inc.’s earnings last quarter?

Vor Biopharma, Inc. released its earnings results on Aug 11, 2026. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$0.857 by -$0.303.

Q: Is Vor Biopharma, Inc. overvalued?

According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Vor Biopharma, Inc. pay dividends?

Vor Biopharma, Inc. does not currently pay dividends.

Q: What is Vor Biopharma, Inc.’s EPS estimate?

Vor Biopharma, Inc.’s EPS estimate is -0.84.

Q: How many shares outstanding does Vor Biopharma, Inc. have?

Vor Biopharma, Inc. has 59,162,292 shares outstanding.

Q: What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?

Vor Biopharma, Inc. reported an EPS of -$1.16 in its last earnings report, missing expectations of -$0.857. Following the earnings report the stock price went up 0.941%.

Q: Which hedge fund is a major shareholder of Vor Biopharma, Inc.?

Currently, no hedge funds are holding shares in VOR

958 Followers

VOR Stock Chart & Stats

$19.26

$0.18(0.93%)

At close: Jul 27 4:00 PM EDT

$19.26

$0.18(0.93%)

Day’s Range― - ―

52-Week Range$6.50 - $50.20

Previous Close$19.41

Volume948.25K

Average Volume (3M)1.54M

Market Cap

$1.38B

Enterprise Value$536.49

Total Cash (Recent Filing)$466.13M

Total Debt (Recent Filing)$2.88M

Price to Earnings (P/E)―

Beta4.67

Next Earnings

Nov 11, 2026

EPS Estimate

-0.84

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-325.79

Shares Outstanding59,162,292

10 Day Avg. Volume884,081

30 Day Avg. Volume1,541,414

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.79

Price to Sales (P/S)0.00

P/FCF Ratio-0.90

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-0.02

Enterprise Value/Ebitda<0.01

Forecast

1Y Price Target

$34.50

Price Target Upside79.13% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-7.15

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Cash RunwayVor’s cash and marketable securities balance of $466.1M plus $48.4M of recent ATM proceeds is projected to fund operations into early 2029. That multi-year runway materially reduces near-term financing pressure and supports continued Phase 3 enrollment and R&D execution without immediate dilution.

Low Absolute LeverageTotal debt of roughly $2.9M is minimal for a clinical-stage biotech, limiting interest expense and preserving borrowing capacity. Low leverage provides financial flexibility to pursue partnerships, staged financings or asset-centric deals while the company advances clinical programs over the next 2–6 months.

Mechanism And Regulatory ValidationConditional approvals in China and TELIGAN’s feature in NEJM validate the BAFF/APRIL-targeting mechanism and demonstrate clinical and regulatory traction via collaborator RemeGen. This strengthens scientific credibility, commercial positioning and partnership prospects for Vor’s platform long-term.

Bears Say

Pre-revenue StatusVor reports zero revenue across all provided periods, reflecting its clinical-stage status. Without product sales, the company must rely on partners or financing to fund operations, leaving revenue visibility low and exposing the business to execution and fundraising risk until commercialization.

High Cash BurnPersistent negative operating cash flow (~-$140M TTM) and free cash flow (~-$141M TTM) indicate a sustained burn rate that consumes liquidity. Even with current cash, continued high burn increases the probability of future capital raises or partnership-driven financing before commercial revenues materialize.

Deeply Negative Shareholders' EquityA roughly -$200M equity position reflects accumulated deficits and weakens the capital base. Negative equity can constrain financing options, affect covenants and investor confidence, and increase dilution risk from future financings—structural limitations for a pre-revenue biotech.

Vor Biopharma News

Vor Bio reports Q2 EPS ($1.16) vs. ($251.24) last year

“We continued to make meaningful progress in 2026 with telitacicept receiving its fourth and fifth commercial approvals in...

4d ago

VOR

Vor Bio sees cash runway into early 2029

Cash, cash equivalents and marketable securities were $466.1 million as of June 30, 2026, which together with the...

4d ago

VOR

Vor Biopharma Adds Industry Veteran David Zaccardelli to Board

Vor Biopharma ( ($VOR) ) has issued an update. On July 6, 2026, Vor Biopharma announced that Board...

1M ago

VOR

Vor Biopharma shareholders back directors and governance measures

The latest update is out from Vor Biopharma ( ($VOR) ). At its 2026 Annual Meeting, Vor Biopharma...

2M ago

VOR

Vor Bio gains boost from telitacicept IgA nephropathy approval

The latest announcement is out from Vor Biopharma ( ($VOR) ). Vor Bio and its collaborator RemeGen Co.,...

2M ago

VOR

Vor Bio announces China NMPA approval for telitacicept

Vor Bio (VOR) and RemeGen announced that China’s National Medicinal Products Administration, or NMPA, has conditionally approved telitacicept...

2M ago

VOR

Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar

Vor Biopharma, Inc. ($VOR) announced an update on their ongoing clinical study. The phase 3 study called “A...

2M ago

VOR

Vor Biopharma: Buy Rating Reiterated on Strong Telitacicept Validation and Autoimmune Growth Runway; $31 Price Target Unchanged

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Vor Biopharma, retaining the price target of...

3M ago

VOR

Vor Bio price target raised to $18 from $15 at Wedbush

Wedbush analyst Martin Fan raised the firm’s price target on Vor Bio (VOR) to $18 from $15 and...

3M ago

VOR

Vor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High

Vor Biopharma, Inc. ($VOR) announced an update on their ongoing clinical study. Vor Biopharma, Inc. is running a...

3M ago

VOR

Vor Bio files to sell 5.34M shares of common stock for holders

16:13 EDT Vor Bio (VOR) files to sell 5.34M shares of common stock for holders Published first on...

4M ago

VOR

Clene, Lovesac, HDFC Bank, State Street, Vor Shock

Insiders have been trading these 5 stocks: (($CLNN)), (($LOVE)), (($HDB)), (($STT)) and (($VOR)). Here is a breakdown of...

4M ago

HDB

STT

Bj’s, Atlas, Academy, Vor, Global-e: Insider Shakeup

Insiders have been trading these 5 stocks: (($BJ)), (($ATLX)), (($ASO)), (($VOR)) and (($GLBE)). Here is a breakdown of...

4M ago

ASO

Vor Bio price target lowered to $31 from $32 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Vor Bio (VOR) to $31 from $32 and keeps a...

4M ago

VOR

VOR FAQ

What was Vor Biopharma, Inc.’s price range in the past 12 months?

Vor Biopharma, Inc. lowest stock price was $6.50 and its highest was $50.20 in the past 12 months.

What is Vor Biopharma, Inc.’s market cap?

Vor Biopharma, Inc.’s market cap is $1.38B.

When is Vor Biopharma, Inc.’s upcoming earnings report date?

Vor Biopharma, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 88 days.

How were Vor Biopharma, Inc.’s earnings last quarter?

Vor Biopharma, Inc. released its earnings results on Aug 11, 2026. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$0.857 by -$0.303.

Is Vor Biopharma, Inc. overvalued?

According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vor Biopharma, Inc. pay dividends?

Vor Biopharma, Inc. does not currently pay dividends.

What is Vor Biopharma, Inc.’s EPS estimate?

Vor Biopharma, Inc.’s EPS estimate is -0.84.

How many shares outstanding does Vor Biopharma, Inc. have?

Vor Biopharma, Inc. has 59,162,292 shares outstanding.

What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?

Vor Biopharma, Inc. reported an EPS of -$1.16 in its last earnings report, missing expectations of -$0.857. Following the earnings report the stock price went up 0.941%.

Which hedge fund is a major shareholder of Vor Biopharma, Inc.?

Currently, no hedge funds are holding shares in VOR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vor Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

134.24%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vor Biopharma, Inc.

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

Vor Biopharma (VOR) Earnings & Revenues

Historic Earnings Reports

VOR Stock 12 Month Forecast

Average Price Target

$34.50

▲(79.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","51":"$51","17.25":"$17.25","28.5":"$28.5","39.75":"$39.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,17.25,28.5,39.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.15,23.369230769230768,25.588461538461537,27.807692307692307,30.026923076923076,32.246153846153845,34.465384615384615,36.684615384615384,38.90384615384615,41.12307692307692,43.34230769230769,45.56153846153846,47.78076923076923,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.15,22.176923076923075,23.203846153846154,24.23076923076923,25.257692307692306,26.284615384615385,27.31153846153846,28.338461538461537,29.365384615384613,30.392307692307693,31.41923076923077,32.44615384615385,33.473076923076924,{"y":34.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.15,21.599999999999998,22.049999999999997,22.5,22.95,23.4,23.849999999999998,24.3,24.75,25.2,25.65,26.1,26.55,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.79,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.39,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.15,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >